Progress in the development of recombinant and synthetic blood-stage malaria vaccines

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Experimental Biology

• Publication date

  2003-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1242/jeb.00646PMID 14506213
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serine Repeat Antigen（SERA5）Is Predominantly Expressed among the SERA Multigene Family of Plasmodium falciparum, and the Acquired Antibody Titers Correlate with Serum Inhibition of the Parasite Growth

  2005cited by this paper
• Malaria vaccines

  2005cited by this paper
• Peripheral blood dendritic cells in children with acute leukaemia and febrile illness

  2004cited by this paper
• Vaccinology: past achievements, present roadblocks and future promises.

  2003cited by this paper
• Vaccination of Monkeys with Recombinant Plasmodium falciparum Apical Membrane Antigen 1 Confers Protection against Blood-Stage Malaria

  2002cited by this paper
• The influence of γδ T cells on the CD4+ T cell and antibody response during a primary Plasmodium chabaudi chabaudi infection in mice

  2002cited by this paper
• Antibody-dependent cellular inhibition assay.

  2002cited by this paper
• Malaria vaccines: from the laboratory to the field.

  2002cited by this paper
• The economic and social burden of malaria

  2002cited by this paper
• The influence of gammadelta T cells on the CD4+ T cell and antibody response during a primary Plasmodium chabaudi chabaudi infection in mice.

  2002cited by this paper
• Immunity to asexual blood stage malaria and vaccine approaches

  2002cited by this paper
• Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys.

  2002cited by this paper
• The role of antibodies to Plasmodium falciparum-infected-erythrocyte surface antigens in naturally acquired immunity to malaria.

  2002influential reference
• Malaria vaccines.

  2002cited by this paper
• Genetic regulation of malaria infection in humans.

  2002cited by this paper
• The pathogenic basis of malaria

  2002cited by this paper
• Serine Repeat Antigen (SERA5) Is Predominantly Expressed among the SERA Multigene Family of Plasmodium falciparum, and the Acquired Antibody Titers Correlate with Serum Inhibition of the Parasite Growth*

  2002influential reference
• Induction of T Helper Type 1 and 2 Responses to 19-Kilodalton Merozoite Surface Protein 1 in Vaccinated Healthy Volunteers and Adults Naturally Exposed to Malaria

  2002cited by this paper
• Vaccines against asexual stage malaria parasites.

  2002cited by this paper
• Functional analysis of Plasmodium falciparum merozoite antigens: implications for erythrocyte invasion and vaccine development.

  2002cited by this paper
• The Mechanism and Significance of Deletion of Parasite-specific CD4+ T Cells in Malaria Infection

  2002cited by this paper
• Progress and challenges for malaria vaccines

  2002cited by this paper
• Immunization of Aotus monkeys with a functional domain of the Plasmodium falciparum variant antigen induces protection against a lethal parasite line

  2002cited by this paper
• Antidisease vaccines.

  2002cited by this paper
• Immunization with a Combination of Merozoite Surface Proteins 4/5 and 1 Enhances Protection against Lethal Challenge with Plasmodium yoelii

  2002cited by this paper
• A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea.

  2002cited by this paper
• Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum.

  2002cited by this paper
• Malaria vaccine trials.

  2002cited by this paper
• Malaria and the immune system in humans.

  2002cited by this paper
• Current developments in malaria transmission-blocking vaccines

  2001cited by this paper
• Selection of Glutamate-Rich Protein Long Synthetic Peptides for Vaccine Development: Antigenicity and Relationship with Clinical Protection and Immunogenicity

  2001cited by this paper
• Specificity of the Protective Antibody Response to Apical Membrane Antigen 1

  2001cited by this paper
• Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.

  2001cited by this paper
• Towards a blood-stage vaccine for malaria: are we following all the leads?

  2001cited by this paper
• New World monkey efficacy trials for malaria vaccine development: critical path or detour?

  2001cited by this paper
• Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen.

  2001cited by this paper
• Peripheral blood dendritic cells in children with acute Plasmodium falciparum malaria.

  2001cited by this paper
• Efficacy of vaccines containing rhoptry-associated proteins RAP1 and RAP2 of Plasmodium falciparum in Saimiri boliviensis monkeys.

  2000cited by this paper
• Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea.

  2000cited by this paper
• Malaria vaccines.

  2000cited by this paper
• Functional conservation of the malaria vaccine antigen MSP-119across distantly related Plasmodium species

  2000cited by this paper
• Human Malaria in Immunocompromised Mice

  2000cited by this paper
• Cytophilic Immunoglobulin Responses to Plasmodium falciparum Glutamate-Rich Protein Are Correlated with Protection against Clinical Malaria in Dielmo, Senegal

  2000cited by this paper
• Human Malaria in Immunocompromised Mice : An In Vivo Model to Study Defense Mechanisms against Plasmodium falciparum

  2000cited by this paper
• Malaria parasite‐specific Th1‐like T cells simultaneously reduce parasitemia and promote disease

  1999influential reference
• Malaria vaccine trials.

  1999cited by this paper
• Immune effector mechanisms in malaria.

  1999cited by this paper
• Differential effect and interaction of monocytes, hyperimmune sera, and immunoglobulin G on the growth of asexual stage Plasmodium falciparum parasites.

  1999cited by this paper
• Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant.

  1999cited by this paper
• The immunogenetics of resistance to malaria.

  1999cited by this paper
• Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid.

  1999cited by this paper
• Demographic impact of vaccination: a review.

  1999cited by this paper
• Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine.

  1998cited by this paper
• Pathways and strategies for developing a malaria blood-stage vaccine.

  1998cited by this paper
• Infection in Mice

  1998cited by this paper
• Pathways for Potentiation of Immunogenicity during Adjuvant-Assisted Immunizations with Plasmodium falciparumMajor Merozoite Surface Protein 1

  1998cited by this paper
• Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria

  1998cited by this paper
• Adjuvants--a classification and review of their modes of action.

  1997cited by this paper
• Identification of a region of PfEMP1 that mediates adherence of Plasmodium falciparum infected erythrocytes to CD36: conserved function with variant sequence.

  1997cited by this paper
• Development of a malaria vaccine.

  1997cited by this paper
• Prolonged Th1‐like response generated by a Plasmodium yoeli‐specific T cell clone allows complete clearance of infection in reconstituted mice

  1997cited by this paper
• Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection

  1996cited by this paper
• Preventing merozoite invasion of erythrocytes.

  1996cited by this paper
• Malaria vaccine development: a multi-immune response approach

  1996cited by this paper
• Gene-targeted mice lacking B cells are unable to eliminate a blood stage malaria infection.

  1996cited by this paper
• Plasmodium falciparum erythrocyte membrane protein 1 is a parasitized erythrocyte receptor for adherence to CD36, thrombospondin, and intercellular adhesion molecule 1.

  1996cited by this paper
• Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.

  1995cited by this paper
• Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages

  1995cited by this paper
• Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum.

  1994cited by this paper
• A novel merozoite surface antigen of Plasmodium falciparum (MSP-3) identified by cellular-antibody cooperative mechanism antigenicity and biological activity of antibodies.

  1994cited by this paper
• Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes

  1994cited by this paper
• Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes.

  1994cited by this paper
• Protective immunity induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: further studies using SERA 1 and MF75.2 adjuvant

  1993cited by this paper
• Use of novel adjuvants and delivery systems to improve the humoral and cellular immune response to malaria vaccine candidate antigens.

  1993cited by this paper
• Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites.

  1993cited by this paper
• Passive immunization of Aotus monkeys with human antibodies to the Plasmodium falciparum antigen Pf155/RESA

  1991cited by this paper
• Characterisation and sequence of a protective rhoptry antigen from Plasmodium falciparum.

  1990cited by this paper
• Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes

  1990cited by this paper
• Malaria vaccines.

  1990cited by this paper
• A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria

  1988cited by this paper
• Adoptive protection against Plasmodium chabaudi adami malaria in athymic nude mice by a cloned T cell line.

  1988cited by this paper
• The protective role of T cells in immunity to malaria.

  1988cited by this paper
• Investigation of the effect of monocytes with Papua New Guinea sera on Plasmodium falciparum in culture.

  1988cited by this paper
• Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications.

  1987cited by this paper
• Induction of protective immunity against experimental infection with malaria using synthetic peptides

  1987cited by this paper
• Kinetic constraints on the development of a malaria vaccine

  1987cited by this paper
• Immunization of Aotus monkeys with recombinant proteins of an erythrocyte surface antigen of Plasmodium falciparum

  1986cited by this paper
• Protective antigens of bloodstage Plasmodium knowlesi parasites.

  1984cited by this paper
• Identification of a strain-specific malarial antigen exposed on the surface of Plasmodium falciparum-infected erythrocytes

  1984cited by this paper
• Erythrocyte entry by malarial parasites. A moving junction between erythrocyte and parasite

  1978cited by this paper
• Invasion of erythrocytes by malaria merozoites.

  1975cited by this paper
• THE PASSIVE TRANSFER OF HUMAN MALARIAL IMMUNITY.

  1964influential reference
• Gamma-Globulin and Acquired Immunity to Human Malaria

  1961cited by this paper
• Gamma globulin.

  1953cited by this paper
• Immunity to asexual blood stage malaria and vaccine approaches

  year unknowncited by this paper

• Genetic diversity and natural selection of plasmodium vivax Merozoite surface protein 8 in global populations.

  2024cites this paper
• Designing a multi-epitope chimeric protein from different potential targets: A potential vaccine candidate against Plasmodium.

  2023cites this paper
• In-silico structural modeling and epitope prediction of highly conserved Plasmodium falciparum protein AMR1.

  2019cites this paper
• Blood-Stage Malaria Parasite Antigens: Structure, Function, and Vaccine Potential.

  2019cites this paper
• Immunogenicity of synthetic peptide constructs based on PvMSP9E795-A808, a linear B-cell epitope of the P. vivax Merozoite Surface Protein-9.

  2019cites this paper
• Genetic polymorphism of merozoite surface proteins 1 and 2 of Plasmodium falciparum in the China–Myanmar border region

  2019cites this paper
• Safety, immunogenicity, and cross-species protection of a plasmid DNA encoding Plasmodium falciparum SERA5 polypeptide, microbial epitopes and chemokine genes in mice and olive baboons

  2017cites this paper
• In silico Identification and Validation of a Linear and Naturally Immunogenic B-Cell Epitope of the Plasmodium vivax Malaria Vaccine Candidate Merozoite Surface Protein-9

  2016cites this paper
• Investigating the Effects of Increasing Anti-AMA1, Anti-MSP1, and Anti-MSP2 In Preventing Malaria Incidence

  2016cites this paper
• Research and Reality: Towards Responsible Medical Research for Catholic Universities

  2015cites this paper
• High-Level Expression of Immunogenic Recombinant Plasmodium vivax Merozoite Surface Protein (Pvmsp-142 kDa) in pGEX 6P1 Vector

  2015cites this paper
• 43 kDa and 66 kDa, two blood stage antigens induce immune response in Plasmodium berghei malaria.

  2014cites this paper
• Recombinant therapeutic protein vaccines.

  2013cites this paper
• Induced by Natural Infection and Anti-Apical Membrane Antigen-1 Antibodies Comparison of Biological Activity of Human

  2013cites this paper
• Sequence analysis of Ancylostoma secreted protein 2 ofNecator americanus from Thai isolates

  2013cites this paper
• Immunity to Malaria : Insights on the Mechanisms Beh ind Effector Functions of Natural Killer Cells

  2012cites this paper
• mRNA expression of cytokines and its impact on outcomes after infection with lethal and nonlethal Plasmodium vinckei parasites

  2012cites this paper
• Impact of pre-existing MSP142-allele specific immunity on potency of an erythrocytic Plasmodium falciparum vaccine

  2012cites this paper
• Important advances in malaria vaccine research

  2012cites this paper
• A Recombinant Plasmodium vivax Apical Membrane Antigen-1 to Detect Human Infection in Iran

  2012cites this paper
• Platform for Plasmodium vivax vaccine discovery and development.

  2011cites this paper
• An eradicating vaccine for Plasmodium falciparum: Possibility or Pipe-dream?

  2011cites this paper
• Feasibility, optimisation and scale-up studies for the production of P. falciparum putative vaccine candidates for a malaria microarray-based antigenicity screening

  2011cites this paper
• Avaliação das propriedades imunogênicas das proteínas 3α e 3β da superfície do merozoíto de Plasmodium vivax

  2011cites this paper
• Identification of a Highly Antigenic Linear B Cell Epitope within Plasmodium vivax Apical Membrane Antigen 1 (AMA-1)

  2011cites this paper
• Effects of vector fusion peptides on the conformation and immune reactivity of epitope-shuffled, recombinant multi-epitope antigens.

  2011cites this paper
• Antibody responses to 43 and 48 kDa antigens of blood-stage Plasmodium berghei in Balb/c mice

  2010cites this paper
• Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection.

  2010cites this paper
• Plasmodium vivax recombinant vaccine candidate AMA-1 plays an important role in adaptive immune response eliciting differentiation of dendritic cells.

  2009cites this paper
• Clinical development of malaria vaccines: Should earlier trials be done in malaria endemic countries?

  2009cites this paper
• A novel Plasmodium falciparum erythrocyte binding protein associated with the merozoite surface, PfDBLMSP.

  2009cites this paper
• Parasitological Evaluation of SC 81458 and SC 83288 , a Novel Class of Drugs against Plasmodium Falciparum

  2009influential citation
• Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates.

  2009cites this paper
• Antibody responses to a panel of Plasmodium falciparum malaria blood-stage antigens in relation to clinical disease outcome in Sudan.

  2009cites this paper
• Chapter 65 – Malaria

  2009cites this paper
• Plasmodium falciparum Merozoite Surface Protein 1 (MSP-1)-MSP-3 Chimeric Protein: Immunogenicity Determined with Human-Compatible Adjuvants and Induction of Protective Immune Response

  2009cites this paper
• Genetic characteristics of polymorphic antigenic markers among Korean isolates of Plasmodium vivax.

  2009cites this paper
• MSP-1p42-specific antibodies affect growth and development of intra-erythrocytic parasites of Plasmodium falciparum

  2009cites this paper
• Prediction of Merozoite Surface Protein 1 and Apical Membrane Antigen 1 Vaccine Efficacies against Plasmodium chabaudi Malaria Based on Prechallenge Antibody Responses

  2008cites this paper
• Characterization of Plasmodium falciparum integral membrane protein Pf25‐IMP and identification of its red blood cell binding sequences inhibiting merozoite invasion in vitro

  2008cites this paper
• Vaccination with a Plasmodium chabaudi adami multivalent DNA vaccine cross-protects A/J mice against challenge with P. c. adami DK and virulent Plasmodium chabaudi chabaudi AS parasites.

  2008cites this paper
• Suppression of Lethal Plasmodium yoelii Malaria following Protective Immunization Requires Antibody-, IL-4-, and IFN-γ-Dependent Responses Induced by Vaccination and/or Challenge Infection1

  2008influential citation
• The Impact of Immunization on Competition Within Plasmodium Infections

  2008cites this paper
• Identification and Characterization of a Novel Plasmodium falciparum Merozoite Apical Protein Involved in Erythrocyte Binding and Invasion

  2008cites this paper
• Comparison of Biological Activity of Human Anti-Apical Membrane Antigen-1 Antibodies Induced by Natural Infection and Vaccination1

  2008cites this paper
• Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacy against Plasmodium chabaudi malaria based on prechallenge antibody responses Running title: Correlates of AMA1 and MSP1 vaccine-induced immunity

  2008cites this paper
• Year-to-year variation in the age-specific incidence of clinical malaria in two potential vaccine testing sites in Mali with different levels of malaria transmission intensity.

  2007cites this paper
• In Immunization with Plasmodium falciparum Apical Membrane Antigen 1, the Specificity of Antibodies Depends on the Species Immunized

  2007cites this paper
• Effect of the malaria vaccine Combination B on merozoite surface antigen 2 diversity.

  2007cites this paper
• Allelic dimorphism-associated restriction of recombination in Plasmodium falciparum msp1.

  2007cites this paper
• Differential antibody responses to Plasmodium falciparum invasion ligand proteins in individuals living in malaria-endemic areas in Brazil and Cameroon.

  2007cites this paper
• Production of High-Affinity Human Monoclonal Antibody Fab Fragments to the 19-Kilodalton C-Terminal Merozoite Surface Protein 1 of Plasmodium falciparum

  2007cites this paper
• High frequency of recombination-driven allelic diversity and temporal variation of Plasmodium falciparum msp1 in Tanzania.

  2007cites this paper
• [Perspectives and challenges of malaria vaccine. Why we must do more].

  2007cites this paper
• Characterization of immune reactivity profiles using microarray technology may expedite identification of candidate antigens for next generation malaria vaccines.

  2007cites this paper
• UNIVERSIDADE DE SÃO PAULO FACULDADE DE CIÊNCIAS FARMACÊUTICAS Programa de Pós-Graduação em Farmácia Área de Análises Clínicas

  2007cites this paper
• Challenge Infection-Dependent Responses Induced by γ Requires Antibody-, IL-4-, and IFN-Malaria following Protective Immunization Plasmodium yoelii Suppression of Lethal

  2007influential citation
• Espoirs et enjeux des stratégies vaccinales contre le paludisme. Pourquoi nous devons faire mieux

  2007cites this paper
• Protection of Rhesus Monkeys by a DNA Prime/Poxvirus Boost Malaria Vaccine Depends on Optimal DNA Priming and Inclusion of Blood Stage Antigens

  2007cites this paper
• Plasmodium vivax serine repeat antigen (SERA) multigene family exhibits similar expression patterns in independent infections.

  2006cites this paper
• Plasmodium rhoptries: how things went pear-shaped.

  2006cites this paper
• Malaria: therapy, genes and vaccines.

  2006cites this paper
• Malaria as a public health problem and status of vaccine development

  2006cites this paper
• Erythrocyte invasion by Babesia parasites: current advances in the elucidation of the molecular interactions between the protozoan ligands and host receptors in the invasion stage.

  2006cites this paper
• Plasmodium falciparum TryThrA antigen synthetic peptides block in vitro merozoite invasion to erythrocytes.

  2006cites this paper
• Optimized Malaria-antigens delivered by immunostimulating reconstituted influenza virosomes

  2006cites this paper
• High road, low road? Choices and challenges on the pathway to a malaria vaccine

  2006cites this paper
• The ecology and evolution of malaria : laboratory studies of Plasmodium chabaudi and its rodent and insect hosts.

  2006cites this paper
• Levels of Plasma Immunoglobulin G with Specificity against the Cysteine-Rich Interdomain Regions of a Semiconserved Plasmodium falciparum Erythrocyte Membrane Protein 1, VAR4, Predict Protection against Malarial Anemia and Febrile Episodes

  2006cites this paper
• Enhanced Protection against Malaria by a Chimeric Merozoite Surface Protein Vaccine

  2006influential citation
• Regulating immunity to malaria

  2006cites this paper
• Induction of Strain-Transcending Immunity against Plasmodium chabaudi adami Malaria with a Multiepitope DNA Vaccine

  2005influential citation
• Relation of nutritional status, immunity, hemoglobinopathy and falciparum malaria infection.

  2005cites this paper
• Malaria with a Multiepitope DNA Vaccine Plasmodium chabaudi adami against Induction of Strain-Transcending Immunity

  2005influential citation
• Analyse protéomique et fonctionnelle des structures de Maurer, un compartiment sécrétoire de Plasmodium falciparum impliqué dans son développement érythrocytaire

  2005cites this paper
• Development of herpes simplex virus 1 vectors for dendritic cell based immunotherapy of malaria

  2005cites this paper
• 8 A Mechanistic Approach to Merozoite Invasion of Red Blood Cells: Merozoite Biogenesis, Rupture, and Invasion of Erythrocytes

  2005cites this paper
• Malaria vaccines in development

  2005cites this paper
• Antibody response profiles induced by Plasmodium falciparum glutamate-rich protein in naturally exposed individuals from a Brazilian area endemic for malaria.

  2005cites this paper
• A novel method for development of malaria vaccines using full-length cDNA libraries.

  2005cites this paper
• CD28 Costimulation Is Required for the Expression of T-Cell-Dependent Cell-Mediated Immunity against Blood-Stage Plasmodium chabaudi Malaria Parasites

  2004cites this paper
• Malaria vaccines for travelers.

  2004cites this paper
• Allelic dimorphism in the merozoite surface protein-3alpha in Korean isolates of Plasmodium vivax.

  2004cites this paper
• Parasites Malaria Plasmodium chabaudi Blood-Stage Cell-Mediated Immunity against Expression of T-Cell-Dependent CD 28 Costimulation Is Required for the

  2004cites this paper
• Utilization of genomic sequence information to develop malaria vaccines

  2003cites this paper